Monitor for underwriter option exercise within 30 days; assess dilution impact given new shares issued and pre-funded warrants outstanding. Evaluate use of proceeds against pipeline milestones to determine capital efficiency.
Price Chart
Executive Summary
Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.
Key Financial Metrics
Key Facts
- Priced public offering of 7,313,582 common shares at $81.00 per share
- Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
- Total gross proceeds: ~$625 million (before expenses)
- Underwriters granted 30-day option to purchase up to 1,157,407 additional shares
- Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
- Offering expected to close on March 12, 2026, subject to customary conditions
Financial Impact
$625 million in gross proceeds, with potential for ~$93.8 million more if underwriters fully exercise option (1,157,407 shares × $81)
Risk Factors
- Significant near-term dilution from new shares and pre-funded warrants
- Proceeds dependent on biotech R&D success, which carries high clinical failure risk
- No guarantee that capital will lead to commercial or regulatory success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access